Led by science.
Evidence before tech.
Melbourne Digital Therapeutics is guided by robust scientific evidence. The MDTx model begins with identifying areas of improvement in current therapeutics. These gaps are translated into actionable research plans, and subsequently, global studies led by veteran scientists. Collaboration across disciplines including neuroscience, linguistics, and engineering places MDTx at the forefront of digital intervention.
Our first innovation.
Our first product, SpeechATTAX, exemplifies MDTx’s science-led approach to digital therapeutics. Developed through rigorous clinical research, SpeechATTAX was evaluated in the world’s largest randomised controlled trial of speech therapy for progressive ataxia, involving 160 participants across four countries. The trial demonstrated significant improvements in speech intelligibility, alongside measurable improvements in vocal control, articulatory precision, and communication outcomes. SpeechATTAX translates this evidence into a clinically validated digital therapeutic designed to improve communication for people living with progressive ataxia.